中重度斑块状银屑病诱导治疗序列的时间效果决策分析模型
该研究采用决策分析模型,在德国医疗体系中比较五种常用及四种以生物制剂起始的诱导治疗序列的时间效果。以PASI-75应答和DLQI最小重要差异计算时间效果比,结果显示生物制剂起始序列更具时间效果,结果对确定性敏感性分析稳健。
要点
- 生物制剂起始序列的时间效果优于传统系统治疗起始序列。
- IXE-INF-SEC序列时间效果比最低,为1.4周/DLQI-MID。
- 政策制定者可考虑将生活质量改善时间作为额外结局指标。
核心结论
- 以生物制剂起始的诱导治疗序列比常用传统序列更具时间效果。
- 决策者分配资源时可考虑将患者生活质量达到MID的时间作为额外结局指标。
研究设计与样本
- 时间效果分析采用决策分析模型,设定于德国医疗体系。
- 模拟人群为符合系统治疗的成人银屑病 vulgaris 或斑块状银屑病患者。
- 干预包括五种德国常用序列(在线专家调查识别,应答率10/15[66.7%])和四种以生物制剂起始的理论序列。
主要发现
- IXE-INF-SEC序列时间效果比为1.4周/DLQI-MID。
- INF-IXE-SEC序列时间效果比为2.05周/DLQI-MID。
- SEC-IXE-ADA序列时间效果比为2.1周/DLQI-MID。
- ADA-IXE-SEC序列时间效果比为2.8周/DLQI-MID。
- MTX-SEC-ADA、MTX-ADA-IXE、MTX-ADA-SEC、MTX-FAE-ADA和FAE-MTX-CSA序列时间效果比分别为6.8、7.0、7.2、10.05和11.5周/DLQI-MID。
关键数值与推荐
- 应答者定义为达到PASI≥75,非应答者为PASI<75。
- 概率值定义为PASI-75应答率。
- 治疗效果由DLQI评分平均变化确定。
- 起效时间评估为25%患者达到PASI-75所需的周数。
- 个体时间效果比计算为起效时间(周)每DLQI最小重要差异(MID)。
临床怎么用
- 临床选择诱导治疗序列时可优先考虑以生物制剂起始的方案以缩短起效时间。
- 评估治疗方案时除疗效和成本外,可纳入生活质量改善时间维度。
局限性
- 模型设定于德国医疗体系,结果外推需谨慎。
- 专家调查应答率为10/15(66.7%),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Systemic psoriasis treatments vary in efficacy and cost but also in time until onset of action. Patients with no response to a first induction treatment are typically switched to another, and some patients require several treatments before they see an improvement. OBJECTIVE: To determine the most cost-effective sequence of induction treatment through a comparative time-effectiveness analysis of different systemic treatment sequences currently licensed in Germany for moderate to severe plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This time-effectiveness analysis used a decision-analytic model set in the German health care system. The population simulated to receive the treatment sequences consisted of adult men and women with psoriasis vulgaris or plaque type psoriasis eligible for systemic treatment. Systematic reviews were performed to generate model input values. Data were collected from November 1 through December 15, 2017, and analyzed from January through August 2018. INTERVENTIONS: Five treatment sequences frequently used in Germany, identified through an online expert survey (response rate, 10 of 15 [66.7%]), and 4 theoretical sequences starting with a biological agent. Treatments included methotrexate sodium (MTX), cyclosporine (CSA), fumaric acid esters (FAE), adalimumab (ADA), ixekizumab (IXE), infliximab (INF), and secukinumab (SEC). MAIN OUTCOMES AND MEASURES: Two health states were defined: responder (patients achieving a Psoriasis Area Severity Index [PASI] ≥75) and nonresponder (PASI <75). Probability values were defined as response rates of PASI-75. Treatment effects were determined by the mean change in Dermatology Life Quality Index (DLQI) score. Time until onset of action was assessed as weeks until 25% of patients reach PASI-75. Individual time-effectiveness ratios were calculated per treatment sequence as time until onset of action (in weeks) per minimally important difference (MID) in DLQI and were subsequently ranked. RESULTS: Treatment sequences starting with a biological agent, including IXE-INF-SEC (1.4 weeks per DLQI-MID), INF-IXE-SEC (2.05 weeks per DLQI-MID), SEC-IXE-ADA (2.1 weeks per DLQI-MID), and ADA-IXE-SEC (2.8 weeks per DLQI-MID) were more time-effective than frequently used treatment sequences, including MTX-SEC-ADA (6.8 weeks per DLQI-MID), MTX-ADA-IXE (7.0 weeks per DLQI-MID), MTX-ADA-SEC (7.2 weeks per DLQI-MID), MTX-FAE-ADA (10.05 weeks per DLQI-MID), and FAE-MTX-CSA (11.5 weeks per DLQI-MID). The results were robust to deterministic sensitivity analyses. CONCLUSIONS AND RELEVANCE: When allocating monetary resources, policy makers and regulators may want to consider time until patients experience an MID in their quality of life as an additional outcome measure. TRIAL REGISTRATION: PROSPERO Identifier: CRD42017074218.
引用
- Zidane M, Dressler C, Gaskins M, et al. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. JAMA Dermatol. 2019. PMID: 31617856. doi:10.1001/jamadermatol.2019.2941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。